Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTAD
PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherla...
Noord Holland Casey Mcdonald Jort Vijverberg Daniel Kontoh Boateng Cognition Therapeutics Inc Company Or Cognition
Source: yahoo.com